GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (NAS:XFOR) » Definitions » Asset Turnover

X4 Pharmaceuticals (X4 Pharmaceuticals) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is X4 Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. X4 Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. X4 Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $160.28 Mil. Therefore, X4 Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. X4 Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -128.94%. It is also linked to ROA % through Du Pont Formula. X4 Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -47.74%.


X4 Pharmaceuticals Asset Turnover Historical Data

The historical data trend for X4 Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X4 Pharmaceuticals Asset Turnover Chart

X4 Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only - 0.02 - - -

X4 Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of X4 Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, X4 Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X4 Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Asset Turnover falls into.



X4 Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

X4 Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (155.586+147.258)/ 2 )
=0/151.422
=0.00

X4 Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (173.293+147.258)/ 2 )
=0/160.2755
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


X4 Pharmaceuticals  (NAS:XFOR) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

X4 Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-76.52/59.3465
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-76.52 / 0)*(0 / 160.2755)*(160.2755/ 59.3465)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*2.7007
=ROA %*Equity Multiplier
=-47.74 %*2.7007
=-128.94 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

X4 Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-76.52/160.2755
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-76.52 / 0)*(0 / 160.2755)
=Net Margin %*Asset Turnover
= %*0
=-47.74 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


X4 Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


X4 Pharmaceuticals (X4 Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.
Executives
Paula Ragan director, officer: President and CEO C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVE., 4TH FLOOR, CAMBRIDGE MA 02139
Mark Baldry officer: Chief Commercial Officer C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arthur Taveras officer: Chief Scientific Officer C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Mary Dibiase officer: Chief Operating Officer 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Adam S. Mostafa officer: See Remarks C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Keith Woods director C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON MA 02134
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Craecker Francoise De director 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Derek M Meisner officer: General Counsel C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Diego Cadavid officer: Chief Medical Officer C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alison Frances Lawton director 39 ROBINSON ROAD, LEXINGTON MA 02420
Renato Skerlj officer: Chief Scientific Officer C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIGE MA 02139
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949

X4 Pharmaceuticals (X4 Pharmaceuticals) Headlines